Please assess the completion status of the following clinical trial:

Trial Title: QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking history of at least 10 pack years~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2009)~* Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) \>40% and \< 80% of the predicted normal value and post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last year.~* Patients requiring long term oxygen therapy on a daily basis for chronic hypoxemia.~* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Any patient with lung cancer or a history of lung cancer (within last 5 years)~* Patients with a history of certain cardiovascular co-morbid conditions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
- fluticasone/salmeterol (Type: ACTIVE_COMPARATOR): Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).

Based on this trial design, predict the completion outcome and termination type (if applicable).